GLP-1 Drugs

GLP-1 Drugs

  • Context:

  • The Drug Controller General of India (DCGI), in collaboration with State Drug Controllers, has intensified regulatory surveillance against the unauthorized sale, promotion, and unsupervised use of GLP-1 (Glucagon-Like Peptide-1 agonist) drugs.

  • With the recent introduction of multiple generic variants of these weight-loss drugs in the Indian market, authorities recently issued a comprehensive advisory explicitly prohibiting surrogate advertisements and off-label usage.

  • This comes amid rising concerns over their on-demand availability through retail pharmacies, online platforms, and wellness clinics

  • About GLP-1 Drugs:

  • GLP-1 drugs are specialized prescription medications primarily developed to treat type 2 diabetes and obesity.

  • They work by correcting hormonal imbalances in the body.

  • Specifically, they mimic the naturally occurring GLP-1 hormone to stimulate the pancreas to release more insulin (which helps cells absorb glucose and lowers blood sugar) and suppress excess glucagon (which prevents the liver from releasing additional glucose into the bloodstream).

  • Additionally, these drugs slow down gastric emptying.

  • This increases the feeling of fullness and decreases the patient's appetite, thereby serving as an effective treatment for obesity and leading to significant weight loss.

  • Recognizing their extreme potency and potential for misuse, India's regulatory authorities have mandated that GLP-1 drugs are strictly not available over the counter.

  • They can only be legally prescribed by highly specialized medical professionals:

  • Endocrinologists

  • Internal medicine specialists

  • Cardiologists.

  • Health Risks of Misuse:

  • The government has issued stern warnings that the unsupervised use of these drugs without clinical oversight can lead to severe health complications.

  • While common side effects include nausea and dizziness, severe and long-term risks involve acute pancreatitis, kidney injury, bowel obstruction, and medullary thyroid cancer.

  • To ensure ethical pharmaceutical practices, the DCGI has warned that businesses breaking the supply chain rules will face strict penal actions, including the immediate cancellation of licenses, heavy fines, and legal prosecution.